151 related articles for article (PubMed ID: 9669469)
21. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
22. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
Benatar M; Mcdermott MP; Sanders DB; Wolfe GI; Barohn RJ; Nowak RJ; Hehir M; Juel V; Katzberg H; Tawil R;
Muscle Nerve; 2016 Mar; 53(3):363-9. PubMed ID: 26179124
[TBL] [Abstract][Full Text] [Related]
24. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
[TBL] [Abstract][Full Text] [Related]
25. The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis.
Munakata R; Utsugisawa K; Nagane Y; Yamagata M; Oikawa M; Obara D; Tohgi H
Eur Neurol; 2002; 48(2):115-7. PubMed ID: 12187003
[No Abstract] [Full Text] [Related]
26. Efficacy and Safety of Low-to-Moderate Dose Oral Corticosteroid Treatment in Ocular Myasthenia Gravis.
Lee YG; Kim US
J Pediatr Ophthalmol Strabismus; 2018 Sep; 55(5):339-342. PubMed ID: 30074608
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
28. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
Mehndiratta MM; Pandey S; Kuntzer T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
[TBL] [Abstract][Full Text] [Related]
29. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.
De Feo LG; Schottlender J; Martelli NA; Molfino NA
Muscle Nerve; 2002 Jul; 26(1):31-6. PubMed ID: 12115946
[TBL] [Abstract][Full Text] [Related]
30. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial.
Benatar M; Sanders DB; Wolfe GI; McDermott MP; Tawil R
Ann N Y Acad Sci; 2012 Dec; 1275():17-22. PubMed ID: 23278573
[TBL] [Abstract][Full Text] [Related]
31. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
Lang B; Dooley J
J Pediatr; 1996 Mar; 128(3):429-32. PubMed ID: 8774518
[TBL] [Abstract][Full Text] [Related]
32. Terbutaline in myasthenia gravis: a pilot study.
Soliven B; Rezania K; Gundogdu B; Harding-Clay B; Oger J; Arnason BG
J Neurol Sci; 2009 Feb; 277(1-2):150-4. PubMed ID: 18952242
[TBL] [Abstract][Full Text] [Related]
33. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
34. [Analysis for the effect of different regimens on ocular myasthenia gravis in children].
Liu C; Wang X; Xie L; Peng J; Wu L; Zheng X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1275-1279. PubMed ID: 29187654
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
36. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial.
Meriggioli MN; Rowin J
J Clin Neurophysiol; 2003; 20(5):382-5. PubMed ID: 14702000
[TBL] [Abstract][Full Text] [Related]
37. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
[TBL] [Abstract][Full Text] [Related]
38. High-dose intravenous methylprednisolone in myasthenia gravis.
Arsura E; Brunner NG; Namba T; Grob D
Arch Neurol; 1985 Dec; 42(12):1149-53. PubMed ID: 4062612
[TBL] [Abstract][Full Text] [Related]
39. Effect of a single pre-operative 125 mg dose of methylprednisolone on postoperative delirium in hip fracture patients; a randomised, double-blind, placebo-controlled trial.
Clemmesen CG; Lunn TH; Kristensen MT; Palm H; Foss NB
Anaesthesia; 2018 Nov; 73(11):1353-1360. PubMed ID: 30151823
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
Lopate G; Pestronk A; Al-Lozi M
Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
